This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Furberg, A.-S. Articles by Thune, I. Search for Related Content PubMed PubMed Citation Articles by Furberg, A.-S. Articles by Thune, I.

Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. The Norwegian EBBA Study

¹ Institute of Community Medicine, Faculty of Medicine, University of Tromsø; ² Department of Radiology, Centre of Breast Imaging, University Hospital of North Norway, Tromsø, Norway; ³ Department of Epidemiology and Population Studies, Institute of Public Health, Jagiellonian University, Krakow, Poland; ⁴ Hormone Laboratory, Aker and the ⁵ Ullevl University Hospital, Oslo, Norway; and ⁶ Department of Anthropology, Harvard University, Cambridge, Massachusetts

Requests for reprints: Anne-Sofie Furberg, Institute of Community Medicine, Faculty of Medicine, University of Tromsø, N-9037 Tromsø, Norway. Phone: 477-764-6351; Fax: 477-764-4831. E-mail: anne-sofie.furberg{at}ism.uit.no

Low serum high-density lipoprotein cholesterol (HDL-C) is an important component of the metabolic syndrome and has recently been related to increased breast cancer risk in overweight and obese women. We therefore questioned whether serum HDL-C might be a biologically sound marker of breast cancer risk. We obtained cross-sectional data among 206 healthy women ages 25 to 35 years who participated in the Norwegian EBBA study. We included salivary ovarian steroid concentrations assessed by daily samples throughout one entire menstrual cycle, metabolic profile with measures of adiposity [body mass index (BMI) and truncal fat percentage], serum concentrations of lipids and hormones (insulin, leptin, testosterone, dehydroepiandrostendione sulfate, insulin-like growth factor-I, and its principal binding protein), and mammographic parenchymal pattern. We examined how components of the metabolic syndrome, including low serum HDL-C, were related to levels of hormones, and free estradiol concentration in particular, and studied predictors of mammographic parenchymal patterns in regression models. In women with BMI 23.6 kg/m² (median), overall average salivary estradiol concentration dropped by 2.4 pmol/L (0.7 pg/mL; 13.2% change in mean for the total population) by each 0.33 mmol/L (12.8 mg/dl; 1SD) increase in serum HDL-C (P = 0.03; P_interaction = 0.03). A subgroup of women characterized by both relatively high BMI (23.6 kg/m²) and high serum LDL-C/HDL-C ratio ( 2.08; 75 percentile) had substantially higher levels of salivary estradiol by cycle day than other women (P = 0.001). BMI was the strongest predictor of overall average estradiol with a direct relationship (P< 0.001). Serum HDL-C was inversely related to serum leptin, insulin, and dehydroepiandrostendione sulfate (P < 0.001, P < 0.01, and P < 0.05, respectively). There was a direct relationship between breast density and healthy metabolic profiles (low BMI, high serum HDL-C; P < 0.001) and salivary progesterone concentrations (P < 0.05). Our findings support the hypothesis that low serum HDL-C might reflect an unfavorable hormonal profile with, in particular, increased levels of estrogens and gives further clues to biomarkers of breast cancer risk especially in overweight and obese women.

Key Words: HDL-C • metabolic profile • ovarian hormones • breast cancer risk

This article has been cited by other articles:

				C M Friedenreich and A E Cust Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects Br. J. Sports Med., August 1, 2008; 42(8): 636 - 647. [Abstract] [Full Text] [PDF]

				A. Ziomkiewicz, P.T. Ellison, S.F. Lipson, I. Thune, and G. Jasienska Body fat, energy balance and estradiol levels: a study based on hormonal profiles from complete menstrual cycles Hum. Reprod., July 18, 2008; (2008) den213v1. [Abstract] [Full Text] [PDF]

				A. Emaus, S. Espetvedt, M.B. Veierod, R. Ballard-Barbash, A.-S. Furberg, P.T. Ellison, G. Jasienska, A. Hjartaker, and I. Thune 17-{beta}-Estradiol in relation to age at menarche and adult obesity in premenopausal women Hum. Reprod., April 1, 2008; 23(4): 919 - 927. [Abstract] [Full Text] [PDF]

				A. E Cust, R. Kaaks, C. Friedenreich, F. Bonnet, M. Laville, A. Tjonneland, A. Olsen, K. Overvad, M. U. Jakobsen, V. Chajes, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Endocr. Relat. Cancer, September 1, 2007; 14(3): 755 - 767. [Abstract] [Full Text] [PDF]

				U. Lim, T. Gayles, H. A. Katki, R. Stolzenberg-Solomon, S. J. Weinstein, P. Pietinen, P. R. Taylor, J. Virtamo, and D. Albanes Serum High-Density Lipoprotein Cholesterol and Risk of Non-Hodgkin Lymphoma Cancer Res., June 1, 2007; 67(11): 5569 - 5574. [Abstract] [Full Text] [PDF]

				D. M. Boudreau, C. M. Rutter, and D. S.M. Buist The influence of statin use on breast density. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1026 - 1029. [Abstract] [Full Text] [PDF]

				C. Diorio, M. Pollak, C. Byrne, B. Masse, N. Hebert-Croteau, M. Yaffe, G. Cote, S. Berube, and J. Brisson Levels of C-Peptide and Mammographic Breast Density Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2661 - 2664. [Abstract] [Full Text] [PDF]

				R. T Chatterton Jr, E. T Mateo, N. Hou, A. W Rademaker, S. Acharya, V C. Jordan, and M. Morrow Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women J. Endocrinol., July 1, 2005; 186(1): 77 - 84. [Abstract] [Full Text] [PDF]